State-of-the-Art – MASLD: New nomenclature and implications for Liver Transplantation

Join us for the next ILTS State-of-the-Art webinar on Dec 1st! Dr. Watt will explain the newly proposed nomenclature for MASLD and examine its potential implications

Event Recording

State-of-the-Art Lecture

MASLD: New nomenclature and implications for Liver Transplantation

December 1

7 pm CET

Follow this link to convert to your time zone.


Discover the latest advancements in liver transplantation as Dr. Watt introduces the newly proposed nomenclature for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and examines its potential implications for the field. Gain valuable insights from a leading expert and stay at the forefront of liver transplantation research.

Webinar objectives

  • Introduce attendees to the recently proposed nomenclature, MASLD, for Metabolic Dysfunction-Associated Steatotic Liver Disease.
  • Discuss the potential impact of MASLD on the diagnosis, management, and stratification of patients undergoing liver transplantation.
  • Analyze the practical implications of adopting MASLD in clinical practice and its potential to improve patient outcomes.

Speaker Details

Kymberly Watt

Speaker

Kymberly D. Watt, M.D., studies long-term outcomes after liver transplantation, with a particular focus on obesity, metabolic syndrome and cardiovascular disease. Dr. Watt also studies recurrent disease, including fatty liver disease and malignancies after liver transplantation. The primary goal of her research is to improve long-term survival in liver transplant recipients by understanding the effects of liver transplantation on these medical issues and minimizing the risk factors associated with these diseases. Dr. Watt studies risk assessment for improving access to transplantation for patients with pre-existing malignancies as well as severe obesity, and metabolic and cardiac disease.

Juan Pablo Arab

Moderator

Dr. Arab is Associate Professor of Medicine at the Division of Gastroenterology, Department of Medicine, and the Department of Epidemiology and Biostatistics at Schulich School of Medicine, Western University, London, Ontario, Canada. Trained at the Pontificia Universidad Catolica, Chile and Mayo Clinic, Rochester, MN, USA. Dr. Arab is a Gastroenterology and Hepatology specialist, Transplant Hepatologist and Clinical Researcher with interest in clinical/translational research and epidemiology in alcohol-related liver disease and non-alcoholic fatty liver disease. He has published more than 160 peer-reviewed papers, co-authored several book chapters and delivered lectures on liver-related topics at national and international meetings.

Zita Galvin

Moderator

Dr Galvin is a transplant hepatologist working in the National Liver Unit in St Vincent’s University Hospital in Dublin, Ireland. She completed her Internal Medicine, Gastroenterology and Hepatology training in Ireland before moving to Canada to do a fellowship in Transplant Hepatology at the Multi Organ Transplant Programme at Toronto General Hospital. She was appointed as Assistant Professor at the University of Toronto and Staff Medical Gastroenterologist and Hepatologist at Toronto General Hospital from 2017 to 2021. Dr. Galvin is passionate about education, teaching and mentorship and completed the Master Teacher Program at the Department of Medicine, University Health Network (UHN).

Event Date

Category